Clinical Trials Logo

Clinical Trial Summary

Magnesium sulfate is the ideal drug for seizures prophilaxis in preeclampsia. The ideal duration of this treatment after delivery is still to be established. The hypothesis is that in stable patients a shorter course of treatment is possible without prejudice to the mother.


Clinical Trial Description

Magnesium sulfate (MgSO4) is certainly the ideal drug for prevention and control of eclamptic seizures. However, there is no consensus on the appropriate duration of prophylaxis with this anticonvulsant postpartum.The objective of the present study is to compare effectiveness of 12 hours of magnesium sulfate versus 24 hours (standard treatment) in stable patients with preeclampsia. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01408979
Study type Interventional
Source Instituto Materno Infantil Prof. Fernando Figueira
Contact
Status Completed
Phase Phase 4
Start date August 2011
Completion date February 2012

See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Active, not recruiting NCT03744988 - Serum Androgen Levels as a Marker for the Severity of Preeclampsia
Completed NCT02189148 - First-trimester Prediction of Preeclampsia
Completed NCT04058405 - Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia
Completed NCT03164304 - Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Phase 4
Not yet recruiting NCT06265415 - Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine N/A
Completed NCT02379832 - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Not yet recruiting NCT01538121 - Antiphospholipid Antibodies and Early Severe Preeclampsia. N/A
Recruiting NCT01906567 - İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? N/A
Recruiting NCT01382732 - Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Phase 3
Completed NCT01538147 - Restless Leg Syndrome and Severe Preeclampsia N/A
Terminated NCT03008616 - Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia Phase 2/Phase 3